Drug intelligence / Profile preview

LIT-00814

Development stage: Phase 1
Lead developer: Shanghai LiteDD
Modality: Small Molecules
Administration: Oral

Overview

LIT-00814 is an orally administered small molecule drug in clinical development for the treatment of advanced solid tumors, including esophageal cancer. The drug is being evaluated in a multicenter, open-label Phase I clinical trial to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. The mechanism of action for LIT-00814 has not been disclosed as of now. Development is primarily taking place in China.

Beyond the preview

Go deeper on LIT-00814.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIT-00814.

Explore the full profile